Rallybio Corp Dossier - Source-backed chat

Rallybio Corp

RLYBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.23

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $16.76Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $89M

Enterprise Value −$3.8M

Shares Outstanding 5.3M diluted

Moat Rating None

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rallybio is undergoing a complete strategic transformation. On May 31, 2026, the company entered into a definitive merger agreement to acquire Avenzo Therapeutics in an all-stock transaction. This reverse merger effectively pivots the company from its legacy rare disease focus to a clinical-stage oncology platform. Upon closing, expected in Q4 2026, the combined company will operate under the name Avenzo Therapeutics, Inc. and trade under the ticker symbol 'AVZO'. Operational control will shift entirely to Avenzo's management team, and Rallybio's New Haven headquarters will close. Pre-merger Rallybio stockholders will retain only a 2.8% economic stake in the combined entity, though they will receive a distribution of substantially all of Rallybio's pre-closing net cash and contingent value rights (CVRs) tied to legacy assets. Given that the legacy pipeline is being discontinued and the stock is transitioning into a vehicle for Avenzo's oncology assets, a 'Hold' is recommended to monitor the closing of the transaction and the initial clinical readouts of Avenzo's CDK inhibitors and bispecific ADCs.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Rallybio's legacy shareholders are heavily diluted to a 2.8% stake in the combined company, and the oncology space for CDK inhibitors and bispecific ADCs is highly competitive, meaning any clinical setbacks or lack of differentiation in early-stage trials could rapidly deplete the cash runway before reaching commercialization.

Base CaseCentral scenario

The merger with Avenzo Therapeutics closes successfully in Q4 2026. Rallybio stockholders receive their pro-rata share of the pre-closing net cash distribution and CVRs, while retaining a 2.8% stake in the newly formed oncology leader. The combined company, backed by a concurrent $215 million private placement, has a cash runway extending into late 2028 to advance its four clinical-stage oncology programs through key milestones.

Bull CaseUpside scenario

The reverse merger with Avenzo Therapeutics transforms Rallybio into a well-capitalized oncology player with a $215 million private placement, funding operations into late 2028 and advancing four clinical-stage precision oncology assets (selective CDK2/CDK4 inhibitors and bispecific ADCs) through key Phase 1/2 milestones.

Scenarios reflect our research view at the research date.

Key Investment Merits

Substantial cash distribution of pre-closing net cash to legacy Rallybio stockholders prior to the merger closing.
Additional upside potential through Contingent Value Rights (CVRs) tied to legacy assets, including the REV102 program.
Transition into a well-capitalized oncology company (Avenzo) backed by a $215 million private placement from top-tier healthcare investors, extending the cash runway into late 2028.

Key Investment Risks

Extreme dilution for legacy Rallybio stockholders, who will own only approximately 2.8% of the combined company post-merger.
Complete discontinuation of Rallybio's legacy rare disease pipeline, meaning legacy clinical assets will no longer drive direct operational value.
Transaction execution risk, including the requirement of stockholder approval and SEC registration effectiveness.

Thesis Invalidation Triggers

Failure to obtain stockholder approval for the merger or the associated reverse stock split.
Termination of the merger agreement by either party, which could trigger a termination fee of up to $20 million payable by Avenzo or $600,000 payable by Rallybio.
Inability to maintain Nasdaq listing compliance prior to the closing of the transaction.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.